KIMS Q2 Results Review - Inline Ebitda; Expansion Plans Slightly Delayed: Prabhudas Lilladher

Prabhudas Lilladher Report

Krishna Institute of Medical Sciences Ltd.'s Q2 operating performance was in-line with our estimate; reported Ebitda growth of 16% YoY to Rs 1.8 billion.

KIMS’ robust cost control, low capital intensive set-up and value accretive acquisitions have ensured good profitability in the past (with Ebitda growth of 34% compound annual growth rate over FY18-23).

Also recent acquisitions of Sunshine, Nashik and Nagpur are value accretive which will continue to aid growth momentum, in our view.

We expect 15% Ebitda CAGR over FY23-25E with healthy return ratios of ~20%. Our FY24E and FY25E Ebitda estimates broadly remains unchanged.

We maintain our ‘Buy’ rating with a target price of Rs 2,000/share (unchanged) based on 22 times September 2025E enterprise value/Ebitda.

At current market price, the stock is trading at 23 times EV/Ebitda (adjusted for partner’s stake) and 38 times price/earning on FY25E.

Any delay in expansion plan will be key risk to our call.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.